Beijing — China’s National Medical Products Administration (NMPA) has ordered a unified revision of the package insert and label for all inosine injection products, requiring marketing authorization holders to file updated documentation with provincial drug regulators before Dec. 1, 2026, following an agency assessment of adverse drug reaction data.
Compliance Snapshot
| Attribute | Detail |
|---|---|
| Announcement | NMPA Announcement No. 87 of 2026 |
| Product scope | All inosine injection products |
| Action required | Unified revision of package insert (and label, where affected) |
| Filing deadline | Dec. 1, 2026 |
| Filing authority | Provincial-level drug regulatory departments |
| Post-filing timeline | Inserts/labels of distributed stock replaced or patients otherwise informed within 9 months |
Clinical Context
Inosine injection, a nucleoside-based metabolic agent, is widely used in China as an adjunct therapy in hepatology, cardiology and hematology settings, including leukopenia and hepatic injury. The NMPA’s decision stems from its post-market adverse drug reaction evaluation program, under which the agency periodically screens nationwide ADR reporting data to identify emerging safety signals in established products. While the announcement does not disclose the specific newly identified reactions, it directs marketing authorization holders to conduct in-depth research into the mechanisms of the added adverse reactions and to strengthen training for physicians and pharmacists on rational use.
Market Impact Analysis
The directive signals the NMPA’s continued tightening of lifecycle safety management for long-marketed injectables, a category that has faced escalating scrutiny since China’s drug administration law reforms placed primary safety accountability on marketing authorization holders. Inosine injection is produced by dozens of domestic manufacturers, meaning the revision effectively resets the labeling baseline for the entire product class at once—a compliance exercise spanning insert revision, label redesign, inventory rotation and patient notification.
For holders, the commercial stakes are modest but the compliance risk is real: products manufactured from the filing date may not use the original insert, and a nine-month window is granted to replace inserts and labels of already-distributed stock or otherwise inform patients of the updates. Provincial regulators are explicitly tasked with enforcement, with violations to be strictly investigated and penalized. The requirement that holders research the mechanisms of newly added adverse reactions and run physician and pharmacist training programs suggests regulators expect the label changes to carry clinically material safety information rather than cosmetic edits.
Forward-Looking Statement
Industry observers expect provincial filings to cluster ahead of the Dec. 1 deadline, followed by a nine-month label-replacement cycle extending into late 2027 for distributed inventory. Clinicians are advised to incorporate the revised benefit-risk profile of inosine injection into prescribing decisions, while patients using the drug should read the updated insert and follow medical guidance strictly. Broader implications point toward continued ADR-driven label harmonization across other legacy injectable products, reinforcing the NMPA’s shift from approval-centric oversight to full lifecycle pharmacovigilance.-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20260904163246192.html